Unique Capabilities are the Foundation for our Success
State-of-the-art cGMP facility
Clinical materials production enabled by the 23,000 sq.ft. cGMP-compliant Laboratory for Cell and Gene Medicine (LCGM; pictured below), one of only fifty academic facilities worldwide. The LCGM manufactures and engineers clinical materials (cells and vectors) to be used with patients. It possesses a rare expertise in manufacturing those treatments and providing support via clinical trial process development, quality systems and regulatory management.
For more information about the LCGM, please visit: https://med.stanford.edu/lcgm.html
Significant investment in translational infrastructure
Stanford's unique capabilities in interdisciplinary and translational research are the direct result of years of recruiting leading scientists in CGT and building dozens of research-oriented institutes, including the Institute for Stem Cell Biology and Regenerative Medicine. Cutting edge technologies, including genetic engineering, functional genomic and immune monitoring are available to study diseases and response to cell and gene therapies. The Cell and Gene Therapy Clinical Trial Office (CGT CTO) provides essential support for first-in-human CGT clinical trials.
Pre-eminent cell and gene therapy program
Over 15 technologies or therapeutics have been licensed in the last decade. Stanford is the largest recipient of NIH funding in the field of cell and gene therapy through grants to faculty, and is the largest recipient of California Institute for Regenerative Medicine (CIRM) funding.
Excellence in clinical care and access to patient populations
Nationally ranked, state-of-the-art hospitals at Stanford Healthcare and Lucile Packard Children’s Hospital facilitate the clinical work of the CDCM and house hundreds of ongoing clinical trials. Dedicated space for cancer and genetic diseases is being created on the fifth floor of LPCH, and the hospital's surgery center features six state-of-the-art operating suites, bringing the total to 13.
The realization of definitive and curative therapies for patients around the world will offer new hope for health, improvement in quality of life, and a reduction in health care costs compared to present palliative, but not curative, therapies.
“Stanford is uniquely positioned to cure the seemingly incurable, thanks to the distinction of our researchers and physicians.”
- Marc Tessier-Lavigne, President, Stanford University
“The CDCM will enable Stanford Medicine to advance its position as a research leader and further its clinical preeminence in Precision Health.”
- Lloyd B. Minor, MD, Dean, School of Medicine
“To bring hope to children and their families is an incredible gift as a physician. The trials we launch at Stanford will undoubtedly change lives.”
- Mary Leonard, Director, Child Health Research Institute
“With nationally ranked hospitals, world-renowned experts, and state-of-the-art facilities, Stanford is leading the field of cell and gene therapy.”
- David Entwistle, President and CEO, Stanford Health Care
“The CDCM is unifying Stanford efforts to advance cell and gene therapy research to bring cures to previously incurable childhood diseases”
- Dennis Lund, MD, Interim CEO, Lucile Packard Children’s Hospital